Our Promise

We will help our partners prevail in their mission to develop needed therapies. We will ensure that high-quality development and imperative urgency remains our focus.

How We Help

Launch Therapeutics offers pharmaceutical and biotech partners a variety of innovative models that provide capital, development expertise, and access to additional resources. These models offer an aligned and efficient approach to help fund and develop late-stage therapies and accelerate the path to regulatory approval. Launch Tx’s team of experts bring an unrivaled combination of immense commitment, decades of experience, and enthusiastic passion to their work.


Bespoke deal structures taking combination of clinical, regulatory, and commercial risks


Team with deep clinical and regulatory expertise with access to an expansive network


Disruptive model accelerating clinical development and regulatory timelines

In The News

Launch Therapeutics partners with Opthea to advance OPT-302, a promising therapy for wet AMD

Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Melbourne, Australia and Boston, MA, USA; 15 August, 2022–Opthea Limited (ASX:OPT; NASDAQ: OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced a non-dilutive financing transaction for up to US$170 million (AU$240 million) from investment funds working with Launch Therapeutics (Launch Tx) to finance and advance the ongoing Phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration (wet AMD). Launch Tx is the recently formed development company backed by funds managed by global investment firm Carlyle (NASDAQ: CG) and its life sciences franchise, Abingworth.